Hmmm--the market doesn't think so... Z is stil off the radar.
That being said, AZN (Astra Zeneca) could be the dark horse here.
They need new drugs badly, and have recently bought Omthera, an early-stage biotech, for a cheap price (instead of paying a fortune for competitor AMRN). The decision to buy Omthera on-the-cheap instead of Amarin--who are competitors in the same space--indictates their strategy may be to buy early-stage promising biotechs as opposed to paying top dollar for biotech companies with recently-approved drugs. ZLCS certainly fits this definition at this point.